CurrentPremera BluecrossPolicy N/A

Upper gastrointestinal (UGI) endoscopy (esophagogastroduodenoscopy, EGD) — indications and site-of-service criteria

Medical necessity criteria for elective diagnostic and certain therapeutic upper GI endoscopy (EGD) in individuals aged 19 and older, including site-of-service guidance and coding. Intended for providers and billing/authorization teams to determine when EGD is covered.

Policy Summary

PayerPremera Bluecross

PolicyUpper gastrointestinal (UGI) endoscopy (esophagogastroduodenoscopy, EGD) — indications and site-of-service criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJul 1, 202620d

Next Review DateN/A

Key ActionDocument the clinical indication and prior therapies (for example, an 8-week continuous daily PPI trial for refractory GERD) when submitting EGD for review.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

19+applies to individuals aged

>=3 monthsminimum duration of GERD/dyspepsia symptoms before EGD (when used as criterion)

8 weeksrequired continuous PPI trial duration for refractory GERD prior to EGD

BMI ≥ 50morbid obesity threshold influencing site-of-service risk

Site-of-service review added (2026-07-01)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

operational constraint noted

Medical Necessity — Indications and Exclusions (EGD)

Medical Necessity — Indications (EGD considered medically necessary when ANY of the following are met)

Covered when ANY of the following malignant, alarm, follow‑up/therapeutic, or GERD/dyspepsia indications are present:

ANY of the following

Malignant / High-risk hereditary conditions
- Barrett esophagus (metaplastic columnar or glandular epithelium)
- Dysplasia (esophageal)
- Esophageal cancer
- Familial adenomatous polyposis (FAP)
- Gastric cancer
- Head/neck cancer
- History of Lynch syndrome / HNPCC
- One evaluation for positive CDH1 mutation
- Family history of gastric, esophageal, or duodenal cancer in a first-degree relative
- Tylosis
- Any situation with clinical features highly suspicious for UGI malignancy (e.g., epigastric mass on x-ray, abnormal barium study)
Alarm symptoms
- Iron deficiency anemia
- Bleeding from rectum or blood in stool (bright red or dark colored)
- Epigastric mass on examination
- Persistent vomiting of unknown cause (including hematemesis)
- Dysphagia (difficulty swallowing)
- Unintentional weight loss of ≥ 3 kg (approx. 6.6 lbs) since symptoms started
Follow-up of known non-malignant conditions / therapeutic uses
- Anorexia of unknown cause
- Evaluation of suspected portal hypertension or cirrhosis to document or treat esophageal varices (see ongoing screening criteria)
- Follow-up of eosinophilic esophagitis
- Follow-up of erosive esophagitis (may need follow-up UGI to evaluate for Barrett after 2-month course of therapy)
- Therapeutic banding (ligation) or sclerotherapy of esophageal varices — repeat UGI until eradication, then surveillance: 1–3 months after eradication, then every 6–12 months thereafter
- Treatment of bleeding lesions (ulcers) — e.g., electrocoagulation, heater probe, laser photocoagulation, injection therapy
GERD/dyspepsia specific
- Refractory GERD/dyspepsia
  - Symptoms present for at least 3 months
  - ANY of the following
    Persist despite 8 weeks of continuous daily PPI therapy
    Symptoms return after PPI therapy has been discontinued
- Severe erosive esophagitis after 2-month course of PPI to assess healing and rule out Barrett esophagus

Not Medically Necessary — When EGD is Not Covered

Not covered when the indications above are not met or in the following scenarios:

ANY of the following

Performed for chronic, non-progressive, atypical UGI symptoms considered functional in origin (except rare one-time exam when unresponsive to therapy)
Performed for uncomplicated heartburn that responds to conservative medical management
Performed when results will not alter management
Performed for evaluation of x-ray findings that are asymptomatic or have responded to therapy (e.g., deformed duodenal bulb asymptomatic, uncomplicated duodenal bulb ulcer responded to therapy, asymptomatic sliding hiatal hernia)
Performed as routine screening of the UGI tract in the absence of a clinical indication

General medically necessary indications (summary from history and updates)

Summary of general medically necessary indications and notable dated clarifications:

ANY of the following

Evaluation of alarm symptoms (e.g., overt GI bleeding, progressive dysphagia, unexplained weight loss, persistent vomiting, evidence of obstruction, iron deficiency anemia)
Persistent GERD or dyspepsia symptoms despite 8 weeks of continuous daily PPI therapy OR symptoms that have returned after PPI therapy has been discontinued
Preoperative evaluation prior to bariatric surgery (policy changed from not medically necessary to medically necessary effective 01/01/23)
Therapeutic interventions for bleeding lesions (electrocoagulation, injection therapy), variceal banding (ligation), sclerotherapy of esophageal varices

Not medically necessary / exclusions (summarized)

Common exclusions and not‑covered situations (summarized):

ANY of the following

Surveillance of healed benign disease (e.g., gastric or duodenal ulcer) is considered not medically necessary
UGI for confirming Helicobacter pylori eradication is considered not medically necessary (added 09/01/25)
UGI for bariatric surgery when bariatric surgery is contractually excluded unless other qualifying symptoms are present (policy clarified 01/01/18)

Specific surveillance timing for Barrett's esophagus (LGD)

When Barrett's esophagus pathology shows low-grade dysplasia, follow this surveillance schedule:

ALL of the following

Repeat UGI at 6 months
Then surveillance at 12 months and annually thereafter

Follow-up of known erosive esophagitis

Follow-up after erosive esophagitis should be performed when the individual has completed a course of therapy:

ALL of the following

Two-month course of therapy under criteria for follow-up of known erosive esophagitis (added 06/01/21)

Site of Service — Medically Necessary and Not Medically Necessary

Site of Service — Medically Necessary

Site-of-service options considered medically necessary when criteria met (preferred = ASC):

ANY of the following

Ambulatory surgical center (ASC) — preferred site when appropriate equipment and physician privileges exist
Off campus-outpatient hospital/medical center
OR
- Individual has a clinical condition placing them at increased risk for complications
  See risk list in children

Site of Service — Not Medically Necessary

Relevant CPT Codes and Historical Informational Codes

EGD CPT codes included in coding sectionCPT

43235	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
43238	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures)
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple
43242	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis)

Informational/removed CPT codes (history notes)CPT

43233	removed - informational
43234	removed - informational
43237	removed - informational
43240	removed - informational
43241	removed - informational
43243	removed - informational
43244	removed - informational
43245	removed - informational
43246	removed - informational
43247	removed - informational

1–10 of 21

1/3

Documentation, Prior Authorization, and Site-of-Service Requirements

Documentation Required

Document clinical indication and prior therapy

Clinical documentation must state the malignant indication, alarm symptoms, high‑risk non‑malignant condition requiring follow‑up or treatment, or prior conservative therapy. For GERD/dyspepsia, include documentation of a trial of continuous daily PPI therapy for 8 weeks (or symptom recurrence after discontinuation).

43235
43239
43238
43242

Prior Authorization

Site-of-service justification for hospital outpatient

If EGD is performed in an outpatient hospital setting rather than an ASC, document why an ASC was not used — e.g., no geographically accessible ASC within 30 miles with necessary equipment, no accessible ASC where the physician has privileges, an ASC guideline excludes use for the individual's condition or weight, patient age ≤18, or the procedure is performed with an additional service requiring the hospital outpatient setting.

Numeric and Clinical Thresholds to Apply

Key thresholds

Minimum GERD symptom duration for screening in older males>= 5 years

Unintentional weight loss alarm threshold>= 3 kg (approx. 6.6 lbs) since symptoms started

PPI trial duration for refractory GERD8 weeks continuous daily PPI

Erosive esophagitis reassessment after PPI2 months of PPI therapy

Morbid obesity site-of-service risk thresholdBMI ≥ 50

COPD pulmonary risk threshold (FEV1)< 50%

Poorly controlled asthma threshold (FEV1)< 80% despite treatment

Policy Definitions and Abbreviations

Definitions

EGDEsophagogastroduodenoscopy; upper gastrointestinal endoscopy.

GERDGastroesophageal reflux disease; symptomatic reflux of stomach contents causing heartburn/regurgitation.

DyspepsiaChronic or recurrent pain or discomfort centered in the upper abdomen.

DysphagiaDifficulty or inability to swallow.

Barrett esophagusReplacement of normal squamous epithelium with metaplastic columnar or glandular epithelium, increasing risk for adenocarcinoma.

ASA classification IIIAmerican Society of Anesthesiologists physical status class III (severe systemic disease).

MELD score

Clinical Background

Upper gastrointestinal endoscopy (EGD/UGI) is a diagnostic and therapeutic procedure used to inspect the esophagus, stomach, and duodenum for causes of heartburn, dysphagia, persistent vomiting, and gastrointestinal bleeding and to perform targeted treatments (e.g., polyp removal, hemostasis, or EUS-guided biopsy).

Professional society guidance emphasizes conservative, noninvasive medical management before pursuing invasive testing: in patients without alarm features, an empiric trial of anti-secretory therapy (commonly an 8-week PPI trial per ACG guidance) or other conservative measures is recommended prior to endoscopy, and endoscopy is reserved for persistent or recurrent symptoms or when alarm signs present.

Surveillance for Barrett esophagus is stratified by the degree of dysplasia: individuals with no dysplasia typically undergo surveillance at extended intervals (generally every 3–5 years), those with low-grade dysplasia require closer follow-up or endoscopic therapy with surveillance at 6 months, then at 12 months and annually thereafter, and high-grade dysplasia generally warrants endoscopic therapy and more intensive surveillance.

Policy Dates and Update Notes

Policy effective date: 2026-07-01. Last reviewed: 2026-06-01. Next review: scheduled per internal cycle (not specified in this document).

Policy Summary

PayerPremera Bluecross

PolicyUpper gastrointestinal (UGI) endoscopy (esophagogastroduodenoscopy, EGD) — indications and site-of-service criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJul 1, 202620d

Next Review DateN/A

Key ActionDocument the clinical indication and prior therapies (for example, an 8-week continuous daily PPI trial for refractory GERD) when submitting EGD for review.

SourceLink

On This Page

History of gastric surgery

NSAID use stopped but symptoms continue

Persistent non-cardiac chest pain after cardiac workup

Odynophagia (painful swallowing)

Barrett esophagus surveillance by pathology

High-grade dysplasia: repeat UGI every 3 months after initial biopsy for 1 year, then annually thereafter
Low-grade dysplasia: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter
No dysplasia (metaplasia): repeat UGI one time within 12 months after initial biopsy; then every 3 years if pathology unchanged

Cirrhosis: at initial diagnosis, one UGI to screen for esophageal varices, then no more frequently than annually for ongoing screening or surveillance

Crohn disease involving esophagus, stomach, or duodenum

Caustic ingestion (assess injury)

Removal of known or suspected foreign body

Gastric, peptic, esophageal ulcer confirmation when conservative management tried and failed or is contraindicated

Follow-up UGI for gastric/peptic/esophageal ulcer every 2 months until healed

Individuals planned for organ transplantation when upper GI pathology might modify management

Endoscopic ultrasound-guided FNA/biopsy of adjacent organs/structures

Preoperative endoscopic evaluation prior to bariatric surgery (unless member's contract excludes bariatric surgery and no other criteria met)

Newly diagnosed (within 1 year) pernicious anemia

Post cardiac ablation for arrhythmias

Screening for Barrett in select patients

Male, aged 50 years or older
≥ 5 years of GERD symptoms
One or more additional risk factors (e.g., nocturnal symptoms, tobacco use, etc.)

To assess diarrhea when small-bowel disease (e.g., celiac disease) or IBD suspected

UGI tract stricture or obstruction

Screening for Barrett in a male individual aged 50 years or older with ≥5 years of GERD symptoms and ≥1 risk factor

Performed for surveillance of healed benign disease (e.g., gastric/duodenal ulcer) unless new indications arise

Surveillance for malignancy not indicated for certain conditions (policy lists examples such as gastric intestinal metaplasia and others where surveillance generally not indicated)

UGI performed for EUS-guided fine needle aspiration/biopsy(s) of adjacent organs or structures (e.g., pancreas, liver) (added 10/01/23)

Follow-up UGI for gastric, peptic, or esophageal ulcer every 2 months until healed

Surveillance for Barrett's esophagus with low-grade dysplasia: repeat UGI at 6 months, then surveillance at 12 months and annually thereafter (03/01/24 update)

Surveillance for individuals with cirrhosis (criteria added 01/01/18 and modified over time)

UGI for assessment of diarrhea when suspicion exists for small bowel disease (e.g., celiac disease) or inflammatory bowel disease (added 01/01/23)

UGI is medically necessary for individuals with prior adenomatous or sessile polyps in gastric, duodenal, or esophageal sites

UGI considered medically necessary for family history of gastric, esophageal, or duodenal cancer in a first-degree relative (clarified 05/01/24)

UGI medically necessary for newly diagnosed (within one year) pernicious anemia (02/01/26 clarification)

When the site-of-service criteria above are not met, the following are not medically necessary:

ALL of the following

Inpatient hospital/medical center
On campus or off-campus outpatient hospital/medical center when the listed site-of-service criteria are not met

Documentation Required

Risk factors for higher-acuity site

When selecting a higher‑acuity site, document patient risks that justify the choice, such as anesthesia risk (ASA III+ or prior anesthesia complications), cardiovascular risks (recent MI <3 months, uncompensated CHF, symptomatic arrhythmia), pulmonary risks (COPD FEV1 <50%, poorly controlled asthma), liver disease (MELD >8), renal failure on dialysis, bleeding disorder or anticipated transfusion need, or morbid obesity (BMI ≥50).

Documentation Required

Barrett esophagus surveillance intervals

For Barrett esophagus surveillance, document the pathology grade (no dysplasia, low‑grade, or high‑grade dysplasia) in the clinical record and apply the policy's specified surveillance intervals based on that grade.

Documentation Required

Document prior PPI therapy for GERD/dyspepsia

When submitting UGI for GERD or dyspepsia, document that symptoms have persisted ≥3 months and that the individual completed an 8‑week trial of continuous daily PPI therapy (or that symptoms recurred after PPI discontinuation).

Documentation Required

Surveillance schedule documentation for Barrett's esophagus with LGD

When pathology shows low‑grade dysplasia (LGD), record the LGD diagnosis and document scheduling of repeat endoscopy at 6 months, then at 12 months, and annually thereafter per policy surveillance timing.

Documentation Required

Document therapeutic indication for endoscopic treatment

For therapeutic endoscopic procedures (e.g., treatment of bleeding lesions, variceal banding/sclerotherapy, EUS‑guided FNA/biopsy), document the lesion and the clinical indication or need for the intervention (e.g., control of bleeding, variceal therapy, tissue diagnosis).

Documentation Required

Preoperative bariatric evaluation

When UGI is performed preoperatively for bariatric surgery, document the clinical indication for the preoperative endoscopy; if the member's contract excludes bariatric surgery, ensure the individual's symptoms independently meet medical necessity criteria.

Prior Authorization

Site of service review (ASC/select procedures)

Effective 2026‑07‑01, site‑of‑service review criteria apply to ASC selection for select diagnostic or surgical procedures; document and follow site‑of‑service authorization requirements. Note: the site‑of‑service review does not apply to Indian Health Services (IHS) facilities.

MELD score liver risk threshold> 8

Recent MI exclusion window for outpatient ASC< 3 months

Barrett's esophagus LGD surveillance intervalRepeat at 6 months, then at 12 months, then annually

Ulcer follow-up interval until healedRepeat every 2 months until healed

This policy applies to adults aged 19+ and documents many historical policy revision events through 2013–2026; operationally, a site-of-service review for select procedures (ASC vs hospital outpatient) was added effective 2026-07-01 and the policy was last revised on 2026-06-01.

Model for End-Stage Liver Disease score used to assess severity of chronic liver disease.

UGIUpper gastrointestinal endoscopy (esophagogastroduodenoscopy) in adults.

LGDLow-grade dysplasia (in Barrett's esophagus).

PPIProton pump inhibitor therapy.

Upper gastrointestinal (UGI) endoscopy (esophagogastroduodenoscopy, EGD) — indications and site-of-service criteria

Medical Necessity — Indications and Exclusions (EGD)

Site of Service — Medically Necessary and Not Medically Necessary

Relevant CPT Codes and Historical Informational Codes

Documentation, Prior Authorization, and Site-of-Service Requirements

Numeric and Clinical Thresholds to Apply

Policy Definitions and Abbreviations

Cross-References

Clinical Background

Policy Dates and Update Notes